Previous 10 | Next 10 |
2023-05-11 11:43:48 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q1 GAAP EPS of -$0.13. Revenue of $0.39M (-58.9% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.13, revenue of $0.39M
– Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera’s pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulatio...
– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore ™ platform – – Patent granted in South Korea and Notice of Allowance received for patent application in Japan for ex...
2023-03-16 10:27:20 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q4 GAAP EPS of -$0.18. Revenue of $0.15M (+114.3% Y/Y). R&D expenses totaled $489 thousand for the three months ended December 31, 2022, compared to $490 thousand for the same period in 2...
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel di...
WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA ) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenie...
WOBURN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced that the company wil...
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that it has completed a private pla...
WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it will be participating in...
Comera Life Sciences press release ( NASDAQ: CMRA ): Q3 GAAP EPS of -$0.20. Revenue of $235M (+167.0% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.20, revenue of $235M
News, Short Squeeze, Breakout and More Instantly...
Comera Life Sciences Holdings Inc. Company Name:
CMRA Stock Symbol:
NASDAQ Market:
Comera Life Sciences Holdings Inc. Website:
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Commercial Metals Company (CMC) is expected to report $1 for Q3 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 GMS Inc. (GMS) is expected to report $2.04 for Q4 2024 China Jo-Jo Drugstores Inc. (CJJD) is expected to report for Q4 2024 Eiger BioPharmaceuticals Inc. (EIGR...
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...